Dyne Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
DYN$17.92-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(492,962) | $(334,259) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 44,263 | 34,625 |
| Depreciation and amortization expense | 1,751 | 1,528 |
| Non-cash lease expense | 433 | 128 |
| Non-cash interest expense | 284 | 62 |
| Accretion of premium on marketable securities | (732) | (1,447) |
| Gain on sale of marketable securities | (3) | (14) |
| Loss on disposal of property and equipment | 30 | 95 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (25,747) | 3,184 |
| Other non-current assets | 4,107 | (12,991) |
| Accounts payable and other liabilities | 15,879 | 17,714 |
| Net cash used in operating activities | (452,697) | (291,375) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (3,748) | (1,436) |
| Purchases of marketable securities | (158,620) | (153,823) |
| Maturities of marketable securities | 92,704 | 135,847 |
| Sales of marketable securities | 61,183 | 8,469 |
| Advance payment for long-lead equipment | — | (18,790) |
| Net cash used in investing activities | (8,481) | (29,733) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock in public offering, net of issuance costs | 404,907 | 215,803 |
| Proceeds from exercise of stock options | 4,074 | 4,633 |
| Proceeds from issuance of long-term debt, net of issuance costs paid | 49,450 | 98,802 |
| Payment of debt issuance costs | (86) | (549) |
| Proceeds from vendor financing arrangement | 34,944 | — |
| Repayments under vendor financing arrangement | (9,587) | — |
| Payment of issuance costs from December 2025 public offering of common stock | (424) | — |
| Proceeds from issuance of common stock in at-the-market offering, net of issuance costs | — | 140,653 |
| Net cash provided by financing activities | 483,278 | 459,342 |
| Net increase in cash, cash equivalents and restricted cash | 22,100 | 138,234 |
| Cash, cash equivalents and restricted cash, beginning of period | 895,740 | 437,391 |
| Cash, cash equivalents and restricted cash, end of period | $917,840 | $575,625 |
| Supplemental disclosures of cash flow information: | ||
| Cash paid for interest | $12,588 | $1,824 |
| Transfer from property and equipment to other non-current assets | $18,790 | $— |
| Right-of-use assets acquired under operating leases | $1,580 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.